基础医学与临床 ›› 2007, Vol. 27 ›› Issue (12): 1314-1318.

• 研究论文 • 上一篇    下一篇

端锚酶和端粒酶反义寡核苷酸联合作用对人肺腺癌细胞A549端粒的影响

卢宏达 黄涛 申雯竹 甄燕 孔庆志   

  1. 武汉市普爱医院 武汉市普爱医院 武汉市普爱医院 武汉市普爱医院 武汉市普爱医院
  • 收稿日期:2007-01-11 修回日期:2007-05-28 出版日期:2007-12-25 发布日期:2007-12-25
  • 通讯作者: 孔庆志

ffect on telomere of antisense tankyrase and telomerase oligonucleotide in human lung adenocarcinoma A549 cells lines

Hong-da LU, Tao HUANG, Wen-zhu SHEN, Yan ZHEN, Qing-zhi KONG   

  1. .Department of traditional Chinese Medicine, Hubei Traditional Chinese Medicine College
  • Received:2007-01-11 Revised:2007-05-28 Online:2007-12-25 Published:2007-12-25
  • Contact: Qing-zhi KONG

摘要: 目的 探讨端锚酶及端粒酶反义寡核苷酸联合作用对A549细胞端粒相关蛋白表达和翻译及对端粒缩短和细胞周期的作用。方法 将A549细胞随机分组为空白对照、sTANKS、shTERT、asTANKS、ashTERT和asTANKS+ ashTERT组,经不同处理,检测hTERT mRNA、端粒酶及端锚酶活性、端粒平均长度及A549细胞寿命。结果 ashTERT能抑制hTERT mRNA表达及蛋白质活性;asTANKS 不影响hTERT mRNA表达,却能抑制端锚酶活性。asTANKS或 ashTERT均可致A549端粒长度缩短,asTANKS+ ashTERT则缩短更为明显,其减少A549细胞平均传代数的作用也明显大于asTANKS或 ashTERT。结论 asTANKS对A549端粒长度的抑制有别于端粒酶途径,不仅能通过影响端锚酶活性缩短肿瘤细胞A549端粒的平均长度,而且可与端粒酶抑制剂协同作用明显缩短肿瘤细胞的生存周期,这可能成为抗癌作用的新靶点。

关键词: 端粒长度, 端锚酶, 端粒酶催化亚单位, 反义寡核苷酸, 人肺腺癌A549细胞

Abstract: Objective The aim of this study is to determine the effect of transcription and translation in telomeric related proteins, and synergism of progressive telomere shortening and cell cycle alteration in human lung adenocarcinoma A549 cell lines, which induced by antisense tankyrase oligonucleotide(asTANKS) combinated with antisense human telomerase reverse transcriptase (ashTERT) oligonucleotide. Methods A549 cells was randomly assigned to 3 groups: ashTERT, ashTERT + asTANKS and asTANKS, while 3 groups (shTERT, sTANKS and blank) as control. With individual intervention for different hours, the effect of transcription in hTERT mRNA was evaluated by RT-PCR, and telomerase activity by ELISA-PCR, tankyrase activity by Western Bloting as well. Moreover, telomere average length was analyzed by Q-FISH, and besides, duration of proliferation was observed by population double test. Results Transcription in hTERT mRNA and telomerase activity for 48h was inhibited obviously by ashTERT , but little done by asTANKS which abated significantly tankyrase activity. Progressive telomere shortening in A549 cells for 48h was evident induced by either asTANKS or ashTERT (Vs control, P<0.01), but it was more severe by combination of them (Vs ashTERT / asTANKS, P<0.01). Furthermore, continuous treatment of ashTERT was similar to asTANKS in duration of proliferation, which was observed 53-57PD and 56-58PD respectively (Vs control, P<0.01), and combinative effect of them conduced to a shorter survival (22-26PD) and earlier cell crisis onset (Vs ashTERT / asTANKS, P<0.01). Conclusions As has been mentioned above, distinguished from other inhibitor concerned with dynamics of telomerase, asTANKS does not only lead to progressive telomere shortening, but also work in coordination with ashTERT in A549 cell lines, which enhanced the efficacy of telomere shortening and hastened earlier cellular crisis. This study provides insight into strategies for telomere-based molecular cancer therapeutics.

Key words: telomere length, tenkyrase (TANKS), human telomerase reverse transcriptase (hTERT), antisense oligonucleotide (ASODN), human lung adenocarcinoma A549 cell lines